Matthew Plotkin
Researcher
Also affiliated: Brigham and Women's Hospital (1996–2001); Harvard University (1996–1997); New York Medical College (2006–2014); University of Arkansas Medical Center (2018); University of Missouri Hospital (2020); Central Arkansas Veterans Healthcare System (2020); Renal Research Institute (2006–2010); Mayo Clinic in Arizona (1993); John L. McClellan Memorial Veterans Hospital (2018–2020)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Matthew Plotkin's research has focused on understanding the molecular mechanisms underlying disease and the development of novel therapeutic strategies. His work has explored the role of epigenetics, specifically DNA methylation, in predicting treatment-induced toxicity. In one publication, he investigated genome-wide DNA methylation signatures to identify early asymptomatic cardiotoxicity in breast cancer patients undergoing doxorubicin treatment. Plotkin's research also touches upon the physiological roles of specific proteins, such as sodium-potassium-chloride symporters, and their implications in conditions like kidney disease, as suggested by his MeSH terms. He has contributed to the field with 26 publications, accumulating over 1,900 citations, and holds an h-index of 16. His scholarly network includes collaborators such as Michael Bauer, Jeanne Y. Wei, and Ping-Ching Hsu, all from the University of Arkansas for Medical Sciences.
Metrics
- h-index: 16
- Publications: 26
- Citations: 1,975
Selected Publications
-
Genome-Wide DNA Methylation Signatures Predict the Early Asymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer (2021)
-
A Uromodulin Mutation Drives Autoimmunity and Kidney Mononuclear Phagocyte Endoplasmic Reticulum Stress (2020)
-
Depletion of senescent-like neuronal cells alleviates cisplatin-induced peripheral neuropathy in mice (2020)
-
Id1 expression in kidney endothelial cells protects against diabetes‐induced microvascular injury (2020)
-
Young blood for old kidneys? More questions than answers so far (2018)
Collaboration Network
Top Collaborators
- Genome-Wide DNA Methylation Signatures Predict the Early Asymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer
- Genome-Wide DNA Methylation Signatures Predict the Early Asymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer
- Genome-Wide DNA Methylation Signatures Predict the Early Asymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer
- Genome-Wide DNA Methylation Signatures Predict the Early Asymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer
- Genome-Wide DNA Methylation Signatures Predict the Early Asymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer
- Genome-Wide DNA Methylation Signatures Predict the Early Asymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer
- Genome-Wide DNA Methylation Signatures Predict the Early Asymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer
- Genome-Wide DNA Methylation Signatures Predict the Early Asymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer
Similar Researchers
Based on overlapping research topics